Details for the presentation are as follows:
Title: Reversal of adenosine-mediated immune suppression by CB-708, an orally bioavailable and potent small molecule inhibitor of CD73
Presenter:
Session Title: Novel Immunomodulatory Agents 2, Abstract #4134
Session Date and Time:
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 25, Board 8
Additional meeting information can be found at the AACR website www.aacr.org. The poster presentation will be available at www.calithera.com in the Publications Section.
CD73 is an enzyme in the tumor microenvironment that produces adenosine, a powerful inhibitor of immune function in tumors. CD73 is expressed across a wide range of tumor types and tumor infiltrating leukocytes. Expression of CD73 often correlates with poor prognosis in patients with cancer. Blockade of adenosine production by CD73 inhibition is expected to reverse immunosuppression in the tumor microenvironment and enhance the immune system’s ability to fight the cancer. CB-708 is an orally bioavailable small molecule inhibitor of CD73.
About Calithera
Calithera is a clinical-stage biopharmaceutical company focused on fighting cancer and other life-threatening diseases by discovering, developing, and commercializing novel small molecule drugs that target tumor and immune cell metabolism. Calithera is headquartered in
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the timing of Calithera’s clinical trials, the review, registration and approval of CB-708 by the
SOURCE:
CONTACT:
ir@Calithera.com
650-870-1071
Source: Calithera Biosciences, Inc.